RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer - Wikidata - awgldk - TriplyDB

RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer

RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer

http://www.wikidata.org/entity/Q34994521

about

Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications Progress toward in vivo use of siRNAs-II Gold nanoclusters-assisted delivery of NGF siRNA for effective treatment of pancreatic cancer.An amino acid-based amphoteric liposomal delivery system for systemic administration of siRNA.Evaluation of dendrimer type bio-reducible polymer as a siRNA delivery carrier for cancer therapy Balancing polymer hydrophobicity for ligand presentation and siRNA delivery in dual function CXCR4 inhibiting polyplexes Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis Therapeutic effects of microRNA-582-5p and -3p on the inhibition of bladder cancer progression.Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer Combination of siRNA-directed Gene Silencing With Cisplatin Reverses Drug Resistance in Human Non-small Cell Lung Cancer.5' Unlocked Nucleic Acid Modification Improves siRNA Targeting.A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors.Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals.Nanotechnology based platforms for survivin targeted drug discovery.siRNA therapeutics in the treatment of diseases.Targeted therapies in bladder cancer: an overview of in vivo research.In vitro targeting of Polo-like kinase 1 in bladder carcinoma: comparative effects of four potent inhibitors.Enhanced inhibition of bladder cancer cell growth by simultaneous knockdown of antiapoptotic Bcl-xL and survivin in combination with chemotherapy.Silencing of Survivin Expression Leads to Reduced Proliferation and Cell Cycle Arrest in Cancer Cells.The Business of RNAi Therapeutics in 2012 Evaluation of in vitro and in vivo therapeutic antitumor efficacy of transduction of polo-like kinase 1 and heat shock transcription factor 1 small interfering RNA MiR-3613-3p affects cell proliferation and cell cycle in hepatocellular carcinoma.Increased endocytosis of magnetic nanoparticles into cancerous urothelial cells versus normal urothelial cells.Nano-BCG: A Promising Delivery System for Treatment of Human Bladder Cancer.Survivin as a novel target protein for reducing the proliferation of cancer cells.

P2860

Q28076060-B9723428-CB65-4FCC-98DA-63E7A4F16C1A Q28255877-4880D7EE-D3B5-4E7C-9AC8-771BB9768B0D Q33629373-B4A3676B-80D6-4289-9695-1B17F27219C8 Q33877242-024B2A2D-CEEC-4C6C-9621-C7F0C9BCE13B Q35691030-C3C48289-7DCE-4637-AF21-FB0EDEB04384 Q35801350-93257020-84F3-45AB-9563-0208E17BFBE4 Q35840236-C55414F2-6BA0-428E-81C9-B245FC47E171 Q36659255-1825764A-ABDF-49D3-B0FF-A7A375DB7EBE Q36877731-4446E8B3-E628-465F-AE01-D562ACC32CD9 Q37065575-04565DA6-FD52-4370-B684-D21DEA5E8454 Q37068331-F34ABA2F-49E8-4B56-B315-993BBE405705 Q37539213-E4F4DE82-4E9B-43F0-AF4C-80B5A495B390 Q37625926-341B0EAC-19C8-4C7E-982D-C59FEB1D7F14 Q37873745-86A4E29A-07CE-45ED-B088-00D7FC7921A7 Q38040859-49F2A5B8-33C6-426F-98DD-3A78F479EEBE Q38074462-62A4639F-8E02-435A-BDF9-8567ED0A359E Q38590471-9192BD71-1463-4A4E-839F-1D0F5B50F384 Q39136346-E3E52F76-B108-4269-B5C4-B402A5EF8D1B Q39142102-5E27495C-E8CB-4C3C-AD07-662B26CC56F9 Q40376534-25579F9A-1D13-415F-AF28-A7245184DD05 Q42212141-998D74E0-BFB7-4683-916E-C70637267C20 Q42676681-28D2A982-AF84-4A3D-83CB-5E0B161A5945 Q46492647-DAF547D1-771D-4AE3-BF4B-9712DBB506D4 Q47777493-C90900F2-3C4E-47B1-98C0-1462F9C38871 Q49164867-911EF256-63E3-4C39-ABF7-E3F58F750847 Q55006767-33C9632D-F994-4F3A-A6C0-37EA6FDCF229

P2860

RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer

http://www.wikidata.org/entity/Q34994521

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer

@ast

RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer

@en

RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer

@nl

type

label

RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer

@ast

RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer

@en

RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer

@nl

prefLabel

RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer

@ast

RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer

@en

RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer

@nl

P1433

Q34994521-CC41D73B-DB2D-4D6F-B352-79B548549C67

P1476

Q34994521-1A217D67-4138-48FD-BDEE-EFB245E50377

P2093

Q34994521-0E27F7F5-2618-4609-80B0-F4EA2B9D4968

Q34994521-189F7800-F89B-45A8-A439-41A4E930A7C7

Q34994521-2428227C-C13B-4ED0-AFB1-68031F9B38BC

Q34994521-2925DA57-6B8A-4E20-8805-E2E630A5CB0F

Q34994521-370F4F15-D7AA-4A3F-9EA1-628144590C3A

Q34994521-463A60D9-E31A-4466-8CA9-58B3B4B75080

Q34994521-4A95E75D-61BE-474D-BBD1-1974238F93A2

Q34994521-4FE7BA9B-9644-4D15-9CDD-730268AB54FA

Q34994521-560CF507-638B-427A-A4CE-41BFA6D4537B

Q34994521-6A1FBBEB-C91E-4553-BF93-824F4F70C3D0

P2860

Q34994521-00281302-4746-4715-BA0E-50A278257FDB

Q34994521-04A2A741-CD81-4F74-B4E9-DFBB2EE2C351

Q34994521-1021825D-D37C-4159-BBA6-92C525D52FCB

Q34994521-142820E8-D0FF-484D-8F26-B78827481216

Q34994521-1BB695F0-6DAB-4ABE-A636-6E5ED7171AC0

Q34994521-1CDE6ABA-8CC3-479F-84C3-4BA499D8FF0D

Q34994521-29028635-5CF4-479D-B29B-3E98EEC4123E

Q34994521-2FE965C5-2C76-45D7-B532-CBB39EF32C62

Q34994521-38597FEC-34BD-47AC-B48C-C7F5104620A4

Q34994521-3CD45EB1-F404-4183-8F7A-48BB102D8FF6

P304

Q34994521-944FE165-9F50-4261-BFA2-3F0FF438A30B

P31

Q34994521-525A867C-424B-4153-93A7-7BE2465F039E

P356

Q34994521-C3FB25C4-64E9-47A1-9FE7-E98EECA8D320

P433

Q34994521-B1B7830A-FC9B-43DF-92E5-6F7C142CBFBE

P478

Q34994521-98C76F18-A91D-4BB8-913C-BBF89351F149

P577

Q34994521-F7AC5EFC-16BA-448A-AD34-1E083A0477F0

P5875

Q34994521-CC159E37-EE92-4235-A81F-391C209C747B

P698

Q34994521-6CF2F044-481F-4053-8235-780069B37615

P932

Q34994521-4399FD76-4ED1-4FBC-80B4-07926DABC0D3

P356

P1433

Molecular Therapy

P1476

RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer

@en

P2093

Akihide Takagi

http://www.w3.org/2001/XMLSchema#string

Alan So

http://www.w3.org/2001/XMLSchema#string

Barry Polisky

http://www.w3.org/2001/XMLSchema#string

Erin Kwang

http://www.w3.org/2001/XMLSchema#string

Feng Chen

http://www.w3.org/2001/XMLSchema#string

Gregory Severson

http://www.w3.org/2001/XMLSchema#string

Iwona Maciagiewicz

http://www.w3.org/2001/XMLSchema#string

Kathy Fosnaugh

http://www.w3.org/2001/XMLSchema#string

Ken Farber

http://www.w3.org/2001/XMLSchema#string

Michael E Houston

http://www.w3.org/2001/XMLSchema#string

P2860

Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7

Targeting survivin in cancer therapy

Polo-like kinases and the orchestration of cell division

siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth.

Bladder cancer detection with urinary survivin, an inhibitor of apoptosis.

The role of antisense oligonucleotides in the treatment of bladder cancer.

Sequence- and target-independent angiogenesis suppression by siRNA via TLR3

Survivin in apoptosis control and cell cycle regulation in cancer.

Antisense oligonucleotide therapy in the management of bladder cancer.

Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects.

P304

928-935

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2011.21

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50250456

http://www.w3.org/2001/XMLSchema#string

P698

21364537

http://www.w3.org/2001/XMLSchema#string

P932

3098637

http://www.w3.org/2001/XMLSchema#string